Citation Impact
Citing Papers
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
2017 Standout
Hypoxia-induced resistance to anticancer drugs is associated with decreased senescence and requires hypoxia-inducible factor-1 activity
2008 StandoutNobel
Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States
2011 Standout
Proliferation Markers Are Associated with MET Expression in Hepatocellular Carcinoma and Predict Tivantinib Sensitivity In Vitro
2017
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
2016 Standout
Factors Associated With Severe Late Toxicity After Concurrent Chemoradiation for Locally Advanced Head and Neck Cancer: An RTOG Analysis
2008 Standout
Apoptosis loss and bcl-2 expression: key determinants of lymph node metastases in T1 breast cancer.
1996
Cytochrome P450 and Non–Cytochrome P450 Oxidative Metabolism: Contributions to the Pharmacokinetics, Safety, and Efficacy of Xenobiotics
2016
Potential of apoptotic pathway-targeted cancer therapeutic research: Where do we stand?
2016
The preterm prediction study: Patterns of cervicovaginal fetal fibronectin as predictors of spontaneous preterm delivery
1997
Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients
2002
Epidemiology and causes of preterm birth
2008 Standout
Premature Rupture of the Fetal Membranes
1998 Standout
Correlation between p53, c-erbB-2, and topoisomerase II? expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications
1999
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
2007 Standout
Prognostic Factors in Breast Cancer
2000
Postoperative Irradiation with or without Concomitant Chemotherapy for Locally Advanced Head and Neck Cancer
2004 Standout
Apoptosis in cancer
2000 Standout
Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2015
Head and neck cancer
2008 Standout
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
2006 Standout
Hyaluronan: from extracellular glue to pericellular cue
2004 Standout
A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin
1999 Standout
Conventional treatments of male infertility in the age of evidence-based andrology
1998
Cancer stem cells revisited
2017 Standout
Postoperative Concurrent Radiotherapy and Chemotherapy for High-Risk Squamous-Cell Carcinoma of the Head and Neck
2004 Standout
Oral Cancer and Precancerous Lesions
2002 Standout
Prognostic value of DNA cytometry in 281 premenopausal patients with lymph node negative breast carcinoma randomized in a control trial
2000
Bcl-2 Family Proteins: Strategies for Overcoming Chemoresistance in Cancer
1997
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival
2009 Standout
Bcl-2 expression in male breast carcinoma
1998
bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study.
1997
Targeting Bcl-2 and Bcl-X with nonpeptidic small-molecule antagonists
2003
Anchor extension: a structure-guided approach to design cyclic peptides targeting enzyme active sites
2021 StandoutNobel
Clinical resistance to topoisomerase-targeted drugs
1998
A radiation therapy oncology group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003
2000 Standout
Targeting apoptosis in cancer therapy
2020 Standout
Epigenetic treatment of solid tumours: a review of clinical trials
2015
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
Light‐Controlled Histone Deacetylase (HDAC) Inhibitors: Towards Photopharmacological Chemotherapy
2015 StandoutNobel
Activity of a Novel bcl-2/bcl-xL-Bispecific Antisense Oligonucleotide Against Tumors of Diverse Histologic Origins
2001
Macrophages are critical effectors of antibody therapies for cancer
2015
Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review
2003 Standout
PI3K/Akt signalling pathway and cancer
2003 Standout
Diffuse large B-cell lymphoma—treatment approaches in the molecular era
2013
Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study
2015
Molecular signals in anti-apoptotic survival pathways
2001
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
2004 Standout
Tumour-associated macrophages as treatment targets in oncology
2017 Standout
The ChEMBL database in 2017
2016 Standout
Akt signalling in health and disease
2011 Standout
The Ki-67 protein: From the known and the unknown
2000 Standout
Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals
2010 Standout
Infertility around the globe: new thinking on gender, reproductive technologies and global movements in the 21st century
2015 Standout
Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy
2006 Standout
Randomized Trial of Radiation Therapy Versus Concomitant Chemotherapy and Radiation Therapy for Advanced-Stage Oropharynx Carcinoma
1999 Standout
Head and Neck Cancer
2001 Standout
PI3K-Akt pathway: Its functions and alterations in human cancer
2004 Standout
Biochemical predictors of preterm labor: fetal fibronectin and salivary estriol
2003
Dual modes of death induced by etoposide in human epithelial tumor cells allow Bcl-2 to inhibit apoptosis without affecting clonogenic survival.
1996
The Bcl-2 Protein Family: Arbiters of Cell Survival
1998 StandoutScience
Data-Mining for Sulfur and Fluorine: An Evaluation of Pharmaceuticals To Reveal Opportunities for Drug Design and Discovery
2013 Standout
Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999.
2000
New and emerging HDAC inhibitors for cancer treatment
2014
American Society of Clinical Oncology Guideline Recommendations for Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer
2005 Standout
An Intergroup Phase III Comparison of Standard Radiation Therapy and Two Schedules of Concurrent Chemoradiotherapy in Patients With Unresectable Squamous Cell Head and Neck Cancer
2002 Standout
Combination therapy in combating cancer
2017 Standout
Hormones and Endocrine-Disrupting Chemicals: Low-Dose Effects and Nonmonotonic Dose Responses
2012 Standout
Precision glycocalyx editing as a strategy for cancer immunotherapy
2016 StandoutNobel
HDACs and HDAC Inhibitors in Cancer Development and Therapy
2016
Mammalian Caspases: Structure, Activation, Substrates, and Functions During Apoptosis
1999 Standout
Mechanisms and clinical relevance of androgens and androgen receptor actions.
2003
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
2018 Standout
Gene Expression Profiling in Breast Cancer: Understanding the Molecular Basis of Histologic Grade To Improve Prognosis
2006 Standout
Macrocyclic Drugs and Clinical Candidates: What Can Medicinal Chemists Learn from Their Properties?
2013
Cell Survival Promoted by the Ras-MAPK Signaling Pathway by Transcription-Dependent and -Independent Mechanisms
1999 StandoutScience
Structural Basis of Type II Topoisomerase Inhibition by the Anticancer Drug Etoposide
2011 StandoutScience
Breast Cancer in Men
2002 Standout
Works of Peter Hellemans being referenced
A Phase I Study of Quisinostat (JNJ-26481585), an Oral Hydroxamate Histone Deacetylase Inhibitor with Evidence of Target Modulation and Antitumor Activity, in Patients with Advanced Solid Tumors
2013
The c-Met Tyrosine Kinase Inhibitor JNJ-38877605 Causes Renal Toxicity through Species-Specific Insoluble Metabolite Formation
2015
Fetal fibronectin detection for prediction of preterm birth in low risk women
1995
Interactions entre le carboplatine, le cisplatine et les rayonnements ionisants dans une lignée cellulaire humaine de cancer ovarien
1999
Phase I and pharmacological study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327 in patients with advanced solid tumours
2010
Prognostic value of bcl-2 expression in invasive breast cancer
1995
Placebo-controlled trial of high-dose Mesterolone treatment of idiopathic male infertility
1991
Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study
2014
Phase 2 Multicenter Trial of Oral Quisinostat, a Histone Deacetylase Inhibitor, in Patients with Previously Treated Stage IB-IVA Cutaneous T-Cell Lymphoma
2012
Immunohistochemical study of topoisomerase II-alpha expression in primary ductal carcinoma of the breast.
1995
Phase Ib study combining ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with CD20-positive B-cell non-Hodgkin lymphoma (NHL).
2013